Last reviewed · How we verify

NCT05498493

Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

Completed NA Last updated 27 September 2024
What this trial tests

NA trial testing Cognitive Rehabilitation in Cognitive Impairment in 67 participants. Completed in 20 August 2024.

Timeline
19 September 2022
Primary endpoint
20 August 2024
20 August 2024

Quick facts

Lead sponsorIcahn School of Medicine at Mount Sinai
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment67
Start date19 September 2022
Primary completion20 August 2024
Estimated completion20 August 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot randomized controlled trial is to investigate the feasibility and efficacy of cognitive rehabilitation for patients with post-COVID-19 cognitive impairment. Additionally, the study will obtain preliminary data, using rsfMRI, regarding the potential underlying connectivity networks, mediating the effect of CR on cognitive improvements.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Preliminary evaluation of a cognitive rehabilitation intervention for post-COVID-19 cognitive impairment: A pilot randomized controlled trial.
    Becker JH, Watson E, Zubair N, Carnavali F, et al · · 2026 · PMID 40991647 · DOI 10.1080/09602011.2025.2552154

Verify or expand the search:

Other trials of Cognitive Rehabilitation

Trials testing the same drug.

Other recruiting trials for Cognitive Impairment

Currently open trials in the same condition.

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05498493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing